Second Line Treatment of EGFR Positive Lung Adenocarcinoma - Our Experience

被引：0

作者：

Seiwerth, Fran ^{[1
]}

Bitar, Lela ^{[1
]}

Markelic, Ivona ^{[1
]}

Dzubur, Fedza ^{[1
]}

Brcic, Luka ^{[2
]}

Seiwerth, Sven ^{[3
]}

Misic, Marija ^{[3
]}

Roglic, Mihovil ^{[1
]}

Plestina, Sanja ^{[1
]}

Cucevic, Branka ^{[1
]}

Kukulj, Suzana ^{[1
]}

Smojver-Jezek, Silvana ^{[1
]}

Samarzija, Miroslav ^{[1
]}

Jakopovic, Marko ^{[1
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Resp Dis Jordanovac, Zagreb, Croatia

[2] Med Univ Graz, Inst Pathol, Graz, Austria

[3] Univ Zagreb, Sch Med, Dept Pathol, Zagreb, Croatia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

EGFR;

D O I：

10.1016/j.jtho.2016.11.1782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-114

引用

页码：S1262 / S1262

页数：1

共 50 条

[41] High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
Moiseyenko, Vladimir M.
Procenko, Svetlana A.
Levchenko, Evgeny V.
Barchuk, Alexey S.
Moiseyenko, Fedor V.
Iyevleva, Aglaya G.
Mitiushkina, Nathalia V.
Togo, Alexandr V.
Semionov, Igor I.
Ivantsov, Alexandr O.
Matsko, Dmitry E.
Imyanitov, Evgeny N.
ONKOLOGIE, 2010, 33 (05): : 231 - 238
[42] Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
Junhui Wang
Jianxin Chen
BMC Cancer, 19
[43] Segmentectomy for Lung Adenocarcinoma: The Impact of EGFR Mutation Status on Recurrence
Hyun, K.
Park, S.
Lee, H. J.
Park, I. K.
Kim, Y.
Kang, C. H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2351 - S2351
[44] Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations
Peterson, Michael R.
Piao, Zhe
Bazhenova, Lyudmila A.
Weidner, Noel
Yi, Eunhee S.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03) : 242 - 247
[45] Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma
Marcoux, N.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S280 - S280
[46] Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Markoczy, Zsolt
Sarosi, Veronika
Kudaba, Iveta
Galffy, Gabriella
Turay, Ulku Yilmaz
Demirkazik, Ahmet
Purkalne, Gunta
Somfay, Attila
Papai-Szekely, Zsolt
Raso, Erzsebet
Ostoros, Gyula
BMC CANCER, 2018, 18
[47] Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Zsolt Markóczy
Veronika Sárosi
Iveta Kudaba
Gabriella Gálffy
Ülkü Yilmaz Turay
Ahmet Demirkazik
Gunta Purkalne
Attila Somfay
Zsolt Pápai-Székely
Erzsébet Rásó
Gyula Ostoros
BMC Cancer, 18
[48] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
Wu, Jenn-Yu
Yu, Chong-Jen
Shih, Jin-Yuan
Yang, Chih-Hsin
Yang, Pan-Chyr
LUNG CANCER, 2010, 67 (03) : 348 - 354
[49] Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
Passaro, Antonio
Pochesci, Alessia
Spitaleri, Gianluca
Catania, Chiara
Noberasco, Cristina
Del Signore, Ester
de Marinis, Filippo
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1283 - 1288
[50] The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
Hung, Ming-Szu
Lung, Jr-Hau
Lin, Yu-Ching
Fang, Yu-Hung
Hsieh, Meng-Jer
Tsai, Ying-Huang
MEDICINE, 2016, 95 (26)

← 1 2 3 4 5 →